STOCK TITAN

Recursion Pharmaceuticals (RXRX) Debt by Year

RXRX NASDAQ

Recursion Pharmaceuticals, Inc. carried $9.6M in long-term debt against $743.3M in cash and equivalents at the end of fiscal year 2025. Long-term debt fell 49.7% from the prior fiscal year. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters Recursion Pharmaceuticals, Inc. has filed alongside them.

FY2025 annual
Long-Term Debt $9.6M
Cash & Equivalents $743.3M
YoY -49.7%
5Y CAGR -3.5%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

RXRX Debt & Cash by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY2310-QFY2210-KFY2110-KFY2010-KFY1910-K
Long-Term Debt$9.6M-49.7%$19.0M+1627.7%$1.1M+105.4%$536K-25.9%$723K-93.7%$11.4MN/A
Cash & Equivalents$743.3M+25.1%$594.4M+51.8%$391.6M-28.8%$549.9M+92.9%$285.1M+8.8%$262.1M+248.7%$75.2M

RXRX Debt & Cash by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-Q
Long-Term Debt$93K-99.2%$4.8M-66.5%$7.2M-56.3%$9.6M-49.7%$11.9M-42.0%$14.2M-38.1%$16.4M+1435.6%$19.0M+1627.7%$20.5M+1721.5%$22.9M+1884.5%$1.1M-9.2%$1.1M+105.4%
Cash & Equivalents$549.9M-16.7%$545.7M+3.9%$654.5M+30.8%$743.3M+25.1%$659.8M+54.3%$525.1M+10.7%$500.5M+68.9%$594.4M+51.8%$427.6M+10.4%$474.3M+16.9%$296.3M-37.4%$391.6M-28.8%

What long-term debt means

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.

More Recursion Pharmaceuticals, Inc. financials

Frequently Asked Questions

Recursion Pharmaceuticals, Inc. carried $9.6M in long-term debt against $743.3M in cash and equivalents at the end of fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) long-term debt fell by 49.7% year over year, from $19.0M to $9.6M in fiscal year 2025.

Recursion Pharmaceuticals, Inc. (RXRX) reported $93K in long-term debt in Q3 2026. This represents a decrease of 99.2% from the same quarter a year earlier.

Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Recursion Pharmaceuticals, Inc. (RXRX) reported on that line in every period on record.